Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.54 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30038196 | 1.00 | MAPK14 (0.54) | MAPK14NR3C1ALDH1A1POLBGPR35 | |
| SCHEMBL25344549 | 0.85 | MAPK14 (0.57) | MAPK14NR3C1GPR35SCN9ATP53 | |
| SCHEMBL20263149 | 0.84 | MAPK14 (0.66) | MAPK14ALDH1A1POLBSCN9ATP53 | |
| SCHEMBL31117130 | 0.84 | RAB9A (0.59) | MAPK14ALDH1A1TP53SMN1; SMN2KMT2A | |
| SCHEMBL4872984 | 0.84 | RAB9A (0.59) | MAPK14ALDH1A1TP53SMN1; SMN2KMT2A | |
| SCHEMBL3376472 | 0.84 | MAPK14 (0.58) | MAPK14NR3C1GPR35SCN9ATP53 | |
| SCHEMBL8045963 | 0.84 | MAPK14 (0.58) | MAPK14NR3C1GPR35SCN9ATP53 | |
| SCHEMBL6159266 | 0.76 | MAPK14 (0.54) | MAPK14NR3C1ALDH1A1GPR35SCN9A | |
| SCHEMBL6161922 | 0.76 | MAPK14 (0.71) | MAPK14 | |
| SCHEMBL14205077 | 0.75 | MAPK14 (0.72) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4424311-A2 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | Cystic Fibrosis Foundation (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-3541390-B1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUND (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| CN-115850268-A | Pyrrolopyrimidines as CFTR potentiators | 囊性纤维化基金会 | 2023-03-28 | — | — | CN | disclosed |
| CN-110337294-B | Pyrrolopyrimidines as CFTR potentiators | 囊性纤维化基金会 | 2022-11-01 | — | — | CN | disclosed |
| US-20210171534-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION | 2021-06-10 | — | — | US | disclosed |
| EP-3554506-B1 | BYCYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUND (US) | 2021-04-28 | — | — | EP | disclosed |
| US-10766904-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2020-09-08 | — | — | US | disclosed |
| US-10766904-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190016728-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20190016728-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20190016727-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-10131670-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180170938-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| WO-2018112149-A1 | BYCYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATON THERAPEUTICS INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20180170938-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180170938-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| WO-2018094137-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171534-A1 | Pyrrolopyrimidines as CFTR Potentiators | CFTR, P2RX1, P2RX5 | MAPK14 4474/4885NR3C1 1484/4885ALDH1A1 3071/4885 |
| US-20190016728-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CFTR, P2RY2, P2RX5 | MAPK14 4031/4885NR3C1 863/4885ALDH1A1 2886/4885 |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CFTR, P2RX1, P2RX5 | MAPK14 4474/4885NR3C1 1484/4885ALDH1A1 3071/4885 |
| US-10131670-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CFTR, P2RY2, P2RX5 | MAPK14 4031/4885NR3C1 863/4885ALDH1A1 2886/4885 |
| US-20180170938-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CFTR, P2RY2, P2RX5 | MAPK14 4031/4885NR3C1 863/4885ALDH1A1 2886/4885 |
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, CLCN2, SLC26A3 | MAPK14 3974/4885NR3C1 912/4885ALDH1A1 3115/4885 |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | MAPK14 4524/4885NR3C1 1577/4885ALDH1A1 2993/4885 |
| US-20190016727-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CFTR, P2RY2, P2RX5 | MAPK14 4031/4885NR3C1 863/4885ALDH1A1 2886/4885 |
| US-10766904-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CFTR, SLC26A3, P2RY2 | MAPK14 3626/4885NR3C1 932/4885ALDH1A1 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.